Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.

Completed

Conditions studied: Multiple Sclerosis

In brief

This was a retrospective cohort study utilizing secondary data from IQVIA's open source pharmacy claims database (i.e., IQVIA LRx) selecting patients with prescription claims for ofatumumab or other DMTs of interest.

Key facts

Study ID

NCT05576779

Run by

Novartis Pharmaceuticals

People needed

2101

Starts

2020-12-03

Expected to finish

2021-12-31

Last updated by the study team

2022-11-08

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with ≥ 1 prescription for ofatumumab in the LRx/Dx database were included. The date of the first observed prescription within the index window served as the index date.
• . Patients with a diagnosis of COVID-19 or a COVID-19 vaccination any time during the study period.
• Patients with linkage to the Dx database.

You may not qualify if…

• No exclusion criteria were applied to patients in the study.

Where it is running

• Novartis Investigative Site — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.